Annual CFF
-$14.28 B
+$6.28 B+30.56%
31 December 2023
Summary:
Novartis AG annual cash flow from financing activities is currently -$14.28 billion, with the most recent change of +$6.28 billion (+30.56%) on 31 December 2023. During the last 3 years, it has fallen by -$12.07 billion (-546.65%). NVS annual CFF is now -446.89% below its all-time high of $4.12 billion, reached on 31 December 2010.NVS Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
-$382.00 M
+$2.82 B+88.06%
30 September 2024
Summary:
Novartis AG quarterly cash flow from financing activities is currently -$382.00 million, with the most recent change of +$2.82 billion (+88.06%) on 30 September 2024. Over the past year, it has increased by +$450.00 million (+54.09%). NVS quarterly CFF is now -105.30% below its all-time high of $7.20 billion, reached on 30 September 2010.NVS Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
-$9.35 B
+$450.00 M+4.59%
30 September 2024
Summary:
Novartis AG TTM cash flow from financing activities is currently -$9.35 billion, with the most recent change of +$450.00 million (+4.59%) on 30 September 2024. Over the past year, it has increased by +$8.31 billion (+47.05%). NVS TTM CFF is now -216.40% below its all-time high of $8.04 billion, reached on 30 September 2010.NVS TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NVS Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +30.6% | +54.1% | +47.0% |
| 3 y3 years | -546.6% | +75.1% | +41.4% |
| 5 y5 years | -236.4% | +85.9% | +21.9% |
NVS Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -546.6% | +30.6% | at high | +96.0% | at high | +56.6% |
| 5 y | 5 years | -546.6% | +30.6% | -120.1% | +96.0% | -1869.0% | +56.6% |
| alltime | all time | -446.9% | +30.6% | -105.3% | +96.0% | -216.4% | +56.6% |
Novartis AG Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$382.00 M(-88.1%) | -$9.35 B(-4.6%) |
| June 2024 | - | -$3.20 B(-38.0%) | -$9.80 B(-4.3%) |
| Mar 2024 | - | -$5.16 B(+750.7%) | -$10.24 B(-28.3%) |
| Dec 2023 | -$14.28 B(-30.6%) | -$607.00 M(-27.0%) | -$14.28 B(-19.2%) |
| Sept 2023 | - | -$832.00 M(-77.1%) | -$17.66 B(-18.1%) |
| June 2023 | - | -$3.64 B(-60.5%) | -$21.57 B(+6.6%) |
| Mar 2023 | - | -$9.20 B(+130.4%) | -$20.24 B(-1.6%) |
| Dec 2022 | -$20.56 B(+26.4%) | -$3.99 B(-15.7%) | -$20.56 B(+3.7%) |
| Sept 2022 | - | -$4.74 B(+105.8%) | -$19.82 B(+19.3%) |
| June 2022 | - | -$2.30 B(-75.8%) | -$16.61 B(-3.7%) |
| Mar 2022 | - | -$9.53 B(+193.1%) | -$17.25 B(+6.1%) |
| Dec 2021 | -$16.26 B(+636.6%) | -$3.25 B(+111.9%) | -$16.26 B(+2.0%) |
| Sept 2021 | - | -$1.53 B(-47.8%) | -$15.95 B(+27.4%) |
| June 2021 | - | -$2.94 B(-65.6%) | -$12.52 B(+6.4%) |
| Mar 2021 | - | -$8.54 B(+190.9%) | -$11.76 B(+432.7%) |
| Dec 2020 | -$2.21 B(-83.8%) | -$2.94 B(-254.5%) | -$2.21 B(+364.8%) |
| Sept 2020 | - | $1.90 B(-187.0%) | -$475.00 M(-90.7%) |
| June 2020 | - | -$2.19 B(-315.7%) | -$5.09 B(+73.6%) |
| Mar 2020 | - | $1.01 B(-184.2%) | -$2.93 B(-78.5%) |
| Dec 2019 | -$13.63 B(+221.1%) | -$1.20 B(-55.7%) | -$13.63 B(+13.8%) |
| Sept 2019 | - | -$2.71 B(+9589.3%) | -$11.97 B(+10.0%) |
| June 2019 | - | -$28.00 M(-99.7%) | -$10.88 B(-12.1%) |
| Mar 2019 | - | -$9.68 B(-2237.5%) | -$12.38 B(+191.7%) |
| Dec 2018 | -$4.24 B(-45.1%) | $453.00 M(-127.9%) | -$4.24 B(-40.2%) |
| Sept 2018 | - | -$1.62 B(+5.9%) | -$7.09 B(-4.3%) |
| June 2018 | - | -$1.53 B(-1.0%) | -$7.41 B(-16.7%) |
| Mar 2018 | - | -$1.55 B(-35.5%) | -$8.89 B(+15.0%) |
| Dec 2017 | -$7.73 B(+45.5%) | -$2.40 B(+23.7%) | -$7.73 B(+1.2%) |
| Sept 2017 | - | -$1.94 B(-35.7%) | -$7.64 B(+26.4%) |
| June 2017 | - | -$3.01 B(+676.3%) | -$6.04 B(+29.3%) |
| Mar 2017 | - | -$388.00 M(-83.2%) | -$4.67 B(-12.0%) |
| Dec 2016 | -$5.31 B(-42.1%) | -$2.30 B(+573.4%) | -$5.31 B(-8.2%) |
| Sept 2016 | - | -$342.00 M(-79.2%) | -$5.79 B(-24.3%) |
| June 2016 | - | -$1.64 B(+59.9%) | -$7.64 B(-9.6%) |
| Mar 2016 | - | -$1.03 B(-63.0%) | -$8.45 B(-7.9%) |
| Dec 2015 | -$9.18 B(+12.6%) | -$2.77 B(+26.4%) | -$9.18 B(+28.5%) |
| Sept 2015 | - | -$2.20 B(-10.4%) | -$7.14 B(+18.5%) |
| June 2015 | - | -$2.45 B(+39.6%) | -$6.03 B(-3.0%) |
| Mar 2015 | - | -$1.75 B(+136.5%) | -$6.21 B(-23.7%) |
| Dec 2014 | -$8.15 B(-7.1%) | -$742.00 M(-31.3%) | -$8.15 B(-8.7%) |
| Sept 2014 | - | -$1.08 B(-59.1%) | -$8.92 B(-3.4%) |
| June 2014 | - | -$2.64 B(-28.5%) | -$9.23 B(+1.3%) |
| Mar 2014 | - | -$3.69 B(+142.9%) | -$9.12 B(+4.0%) |
| Dec 2013 | -$8.77 B | -$1.52 B(+9.1%) | -$8.77 B(+4.5%) |
| Sept 2013 | - | -$1.39 B(-44.7%) | -$8.39 B(-7.9%) |
| June 2013 | - | -$2.52 B(-24.6%) | -$9.12 B(+10.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2013 | - | -$3.34 B(+192.0%) | -$8.27 B(+23.9%) |
| Dec 2012 | -$6.67 B(-55.6%) | -$1.14 B(-46.0%) | -$6.67 B(-31.5%) |
| Sept 2012 | - | -$2.12 B(+26.6%) | -$9.75 B(-14.4%) |
| June 2012 | - | -$1.67 B(-4.0%) | -$11.39 B(-30.0%) |
| Mar 2012 | - | -$1.74 B(-58.7%) | -$16.28 B(+8.4%) |
| Dec 2011 | -$15.02 B(-465.0%) | -$4.22 B(+12.2%) | -$15.02 B(+1.1%) |
| Sept 2011 | - | -$3.76 B(-42.7%) | -$14.86 B(+281.1%) |
| June 2011 | - | -$6.56 B(+1246.4%) | -$3.90 B(-208.1%) |
| Mar 2011 | - | -$487.00 M(-88.0%) | $3.61 B(-12.4%) |
| Dec 2010 | $4.12 B(+46.5%) | -$4.06 B(-156.4%) | $4.12 B(-48.8%) |
| Sept 2010 | - | $7.20 B(+658.3%) | $8.04 B(+530.7%) |
| June 2010 | - | $950.00 M(+4218.2%) | $1.27 B(-46.4%) |
| Mar 2010 | - | $22.00 M(-115.6%) | $2.38 B(-15.3%) |
| Dec 2009 | $2.81 B(-209.2%) | -$141.00 M(-131.8%) | $2.81 B(-452.0%) |
| Sept 2009 | - | $443.00 M(-78.4%) | -$798.00 M(+43.5%) |
| June 2009 | - | $2.06 B(+354.6%) | -$556.00 M(-135.5%) |
| Mar 2009 | - | $452.00 M(-112.1%) | $1.57 B(-160.9%) |
| Dec 2008 | -$2.57 B(-72.4%) | -$3.75 B(-647.2%) | -$2.57 B(+29.9%) |
| Sept 2008 | - | $685.00 M(-83.6%) | -$1.98 B(-64.2%) |
| June 2008 | - | $4.18 B(-213.3%) | -$5.54 B(-47.4%) |
| Mar 2008 | - | -$3.69 B(+16.9%) | -$10.53 B(+13.0%) |
| Dec 2007 | -$9.32 B(+89.0%) | -$3.16 B(+9.9%) | -$9.32 B(+15.5%) |
| Sept 2007 | - | -$2.87 B(+254.7%) | -$8.06 B(+42.3%) |
| June 2007 | - | -$810.00 M(-67.3%) | -$5.67 B(+0.1%) |
| Mar 2007 | - | -$2.48 B(+30.3%) | -$5.66 B(+14.8%) |
| Dec 2006 | -$4.93 B(+1719.6%) | -$1.90 B(+300.6%) | -$4.93 B(+300.2%) |
| Sept 2006 | - | -$475.00 M(-41.0%) | -$1.23 B(-9.0%) |
| June 2006 | - | -$805.00 M(-53.9%) | -$1.35 B(-223.4%) |
| Mar 2006 | - | -$1.75 B(-197.3%) | $1.10 B(-504.8%) |
| Dec 2005 | -$271.00 M(-91.0%) | $1.80 B(-400.8%) | -$271.00 M(-77.6%) |
| Sept 2005 | - | -$597.00 M(-136.3%) | -$1.21 B(-18.2%) |
| June 2005 | - | $1.65 B(-152.8%) | -$1.48 B(-61.8%) |
| Mar 2005 | - | -$3.12 B(-462.7%) | -$3.86 B(+28.8%) |
| Dec 2004 | -$3.00 B(-47.7%) | $859.00 M(-199.3%) | -$3.00 B(-32.1%) |
| Sept 2004 | - | -$865.00 M(+16.9%) | -$4.41 B(-0.3%) |
| June 2004 | - | -$740.00 M(-67.1%) | -$4.43 B(-29.5%) |
| Mar 2004 | - | -$2.25 B(+305.0%) | -$6.28 B(+9.5%) |
| Dec 2003 | -$5.73 B(+41.8%) | -$556.00 M(-36.7%) | -$5.73 B(+10.7%) |
| Sept 2003 | - | -$879.00 M(-66.1%) | -$5.18 B(+20.5%) |
| June 2003 | - | -$2.59 B(+51.7%) | -$4.30 B(+151.7%) |
| Mar 2003 | - | -$1.71 B | -$1.71 B |
| Dec 2002 | -$4.04 B(+2394.4%) | - | - |
| Dec 2001 | -$162.00 M(-94.5%) | - | - |
| Dec 2000 | -$2.95 B(+8.6%) | - | - |
| Dec 1999 | -$2.71 B(+16.2%) | - | - |
| Dec 1998 | -$2.34 B | - | - |
FAQ
- What is Novartis AG annual cash flow from financing activities?
- What is the all time high annual CFF for Novartis AG?
- What is Novartis AG annual CFF year-on-year change?
- What is Novartis AG quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Novartis AG?
- What is Novartis AG quarterly CFF year-on-year change?
- What is Novartis AG TTM cash flow from financing activities?
- What is the all time high TTM CFF for Novartis AG?
- What is Novartis AG TTM CFF year-on-year change?
What is Novartis AG annual cash flow from financing activities?
The current annual CFF of NVS is -$14.28 B
What is the all time high annual CFF for Novartis AG?
Novartis AG all-time high annual cash flow from financing activities is $4.12 B
What is Novartis AG annual CFF year-on-year change?
Over the past year, NVS annual cash flow from financing activities has changed by +$6.28 B (+30.56%)
What is Novartis AG quarterly cash flow from financing activities?
The current quarterly CFF of NVS is -$382.00 M
What is the all time high quarterly CFF for Novartis AG?
Novartis AG all-time high quarterly cash flow from financing activities is $7.20 B
What is Novartis AG quarterly CFF year-on-year change?
Over the past year, NVS quarterly cash flow from financing activities has changed by +$450.00 M (+54.09%)
What is Novartis AG TTM cash flow from financing activities?
The current TTM CFF of NVS is -$9.35 B
What is the all time high TTM CFF for Novartis AG?
Novartis AG all-time high TTM cash flow from financing activities is $8.04 B
What is Novartis AG TTM CFF year-on-year change?
Over the past year, NVS TTM cash flow from financing activities has changed by +$8.31 B (+47.05%)